Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5239386 | 0.88 | DPP4 (0.35) | DPP4TLR7TDP1CXCR3CACNA2D1 | |
| SCHEMBL5237505 | 0.86 | DPP4 (0.44) | DPP4TLR7TDP1KDM4EKMT2A | |
| SCHEMBL5236379 | 0.85 | DPP4 (0.43) | DPP4TDP1KDM4EKMT2ATSHR | |
| SCHEMBL5270279 | 0.85 | PGR (0.42) | DPP4TDP1KDM4EKMT2ATSHR | |
| SCHEMBL5237435 | 0.85 | DPP4 (0.38) | DPP4TDP1KDM4EKMT2ATSHR | |
| SCHEMBL5231346 | 0.85 | ALDH1A1 (0.41) | DPP4KDM4EKMT2A | |
| SCHEMBL5234735 | 0.84 | DPP4 (0.37) | DPP4TDP1KDM4EKMT2ATSHR | |
| SCHEMBL5236554 | 0.84 | DPP4 (0.48) | DPP4KDM4EKMT2A | |
| SCHEMBL5237315 | 0.84 | DPP4 (0.42) | DPP4TDP1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL5236092 | 0.82 | DPP4 (0.33) | DPP4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | DPP4 2/4885TLR7 2033/4885TDP1 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.